$29.04
1.69% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Structure Therapeutics Stock price

$29.04
-4.71 13.96% 1M
-10.10 25.80% 6M
-11.72 28.75% YTD
-7.26 20.00% 1Y
+14.04 93.60% 3Y
+14.04 93.60% 5Y
+14.04 93.60% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.50 1.69%
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Key metrics

Market capitalization $1.66b
Enterprise Value $751.76m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.85
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-142.66m
Free Cash Flow (TTM) Free Cash Flow $-104.60m
Cash position $915.29m
EPS (TTM) EPS $-2.21
P/E forward negative
Short interest 21.67%
Show more

Is Structure Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Structure Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Structure Therapeutics forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Structure Therapeutics forecast:

Buy
100%

Financial data from Structure Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.44 1.44
78% 78%
-
-1.44 -1.44
78% 78%
-
- Selling and Administrative Expenses 44 44
79% 79%
-
- Research and Development Expense 96 96
65% 65%
-
-141 -141
69% 69%
-
- Depreciation and Amortization 1.44 1.44
78% 78%
-
EBIT (Operating Income) EBIT -143 -143
69% 69%
-
Net Profit -111 -111
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Structure Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Structure Therapeutics Stock News

Neutral
GlobeNewsWire
11 days ago
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
Neutral
GlobeNewsWire
about one month ago
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference...
Neutral
GlobeNewsWire
about 2 months ago
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290  over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study  to evaluate even higher doses of GSBR-1290 over 36 weeks;  first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conferenc...
More Structure Therapeutics News

Company Profile

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

Head office Cayman Islands
CEO Raymond Stevens
Employees 93
Founded 2019
Website www.structuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today